These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8436150)

  • 1. Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study.
    Arzilli F; Gandolfi E; Del Prato C; Innocenti P; Ponzanelli F; Caiazza A; Ghisoni F; Saba P; Giuntoli F; Borgnino C
    Eur J Clin Pharmacol; 1993; 44(1):23-5. PubMed ID: 8436150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring.
    Fogari R; Malacco E; Tettamanti F; Gnemmi AE; Milani M
    Br J Clin Pharmacol; 1993 Jan; 35(1):51-4. PubMed ID: 8448068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isradipine: a slow-release formulation given once daily controls blood pressure for 24 h.
    Holmes DG
    Am J Hypertens; 1993 Mar; 6(3 Pt 2):74S-76S. PubMed ID: 8466733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of isradipine SRO and enalapril in black patients with mild-to-moderate hypertension.
    Maharaj B; van der Byl K
    Am J Hypertens; 1993 Mar; 6(3 Pt 2):80S-81S. PubMed ID: 8466735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does isradipine modified release 5 mg once daily reduce blood pressure for 24 hours?
    Celis H; Staessen J; Fagard R; Thijs L; Amery A
    J Cardiovasc Pharmacol; 1993 Aug; 22(2):300-4. PubMed ID: 7692173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study.
    Hermans L; Deblander A; De Keyser P; Scheys I; Lesaffre E; Westelinck KJ
    Br J Clin Pharmacol; 1994 Oct; 38(4):335-40. PubMed ID: 7833223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the antihypertensive efficacy of once-daily sustained-release isradipine and lacidipine using 24-hour ambulatory blood-pressure monitoring.
    Galderisi M; Petrocelli A; Garofalo M; Celentano A; Alfieri A; de Divitiis O
    J Int Med Res; 1995; 23(4):234-43. PubMed ID: 7589766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Brazilian multicenter study to evaluate the clinical effectiveness and tolerance of isradipine SRO using ambulatory monitoring of arterial pressure in the treatment of mild and moderate arterial hypertension].
    Magliano MF; Amodeo C; Mion Júnior D; Francischetti E; Lima Júnior E; Nobre F; Chaves H; Ribeiro JM; Spritzer N; Jardim PC
    Arq Bras Cardiol; 1993 Nov; 61(5):311-8. PubMed ID: 8147731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the antihypertensive efficacy of isradipine SRO as assessed by ambulatory blood pressure determination].
    Waeber B; Soret P; Poget PN; Brunner HR
    Schweiz Rundsch Med Prax; 1992 Dec; 81(50):1514-7. PubMed ID: 1465521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.
    Ranieri G; Filitti V; Andriani A; Bonfantino MV; Lamontanara G; Cavallo A; Milani M; De Cesaris R
    Cardiovasc Drugs Ther; 1996 May; 10(2):119-23. PubMed ID: 8842503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained blood pressure control with controlled-release isradipine (isradipine-CR).
    Chrysant SG; Cohen M
    J Clin Pharmacol; 1995 Mar; 35(3):239-43. PubMed ID: 7608311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Circadian antihypertensive effect of sustained-release isradipine in patients with essential hypertension in comparison to placebo].
    Burger KJ; Anlauf M
    Arzneimittelforschung; 1993 Sep; 43(9):958-62. PubMed ID: 8240458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effect of slow-release nicardipine. A placebo-controlled cross-over study.
    Salvetti A; Cardellino G; Pesenti M; Caiazza A; Ghisoni F; Del Prato C; Innocenti PF; Ponzanelli F; Errico M; Freda M
    Eur J Clin Pharmacol; 1989; 36(5):439-42. PubMed ID: 2666139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure.
    Portaluppi F; Vergnani L; Manfredini R; degli Uberti EC; Fersini C
    Am J Hypertens; 1995 Jul; 8(7):719-26. PubMed ID: 7546498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure.
    Lacourcière Y; Poirier L; Dion D; Provencher P
    Am J Cardiol; 1990 Feb; 65(7):467-72. PubMed ID: 2137666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Circadian antihypertensive action and tolerability of a sustained-release form of isradipine in an intra-individual comparison with nitrendipine].
    Lohmann FW; Welzel D; Burger KJ
    Arzneimittelforschung; 1993 May; 43(5):522-5. PubMed ID: 8328996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.